Copyright 2008 Medical News Today Latest Clinical Trials / Drug Trials News From Medical News Today. http://www.medicalnewstoday.com/sections/clinical_trials/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Sat, 05 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/113910.php ORLANDO, FL (UroToday.com) - (Annual Meeting of the American Urological Association) There were several clinical trials evaluating the role of alpha blockers in patients with Ureteral calculi. Alpha blockers did not seem beneficial for patients with untreated Ureteral calculi. However, alpha blockers did improve stone passage in patients who had ureteroscopic manipulation/laser therapy of the Ureteral stone. Fri, 04 Jul 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/113908.php Titan Pharmaceuticals, Inc. (AMEX:TTP) announced initial analyses show that Spheramine® did not meet the Phase IIb clinical study's primary or key secondary endpoints, with no significant differences detected between the Spheramine and sham surgery arms of the study after 12 months of follow-up. Fri, 04 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113904.php Omrix Biopharmaceuticals, Inc. ("Omrix" or the "Company") (NASDAQ: OMRI) announced that it has enrolled its first patient in a Phase II clinical trial in Israel for its Fibrin Pad product candidate. This is the first clinical trial that will evaluate the Fibrin Pad's performance in surgery where severe bleeding is present and the product is applied directly onto a solid organ. The Phase II clinical trial in Israel is being conducted simultaneously with the Phase II clinical trial in the U.S. Fri, 04 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/113870.php Movetis NV, a European specialist pharmaceutical company, announced that M0002 is progressing to phase IIb following positive results of a phase IIa multiple-dosing trial for the treatment of ascites, the accumulation of fluid in the abdomen in patients with liver cirrhosis resulting from liver conditions such as hepatitis C, hepatitis B or alcoholism. Thu, 03 Jul 2008 12:00:00 PDT http://www.medicalnewstoday.com/articles/113890.php A study by an international team of researchers found that an experimental drug that stops blood vessels that feed tumors from forming was able, in a small number of patients, to slow down the progression of advanced thyroid cancer that has spread to other sites. Thu, 03 Jul 2008 05:00:00 PDT http://www.medicalnewstoday.com/articles/113843.php SCOLR Pharma, Inc. (AMEX: DDD) announced the initiation of the third of three pivotal trials to evaluate the safety and efficacy of its formulation of 12-hour extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The Company expects to complete the trial in late 2008. If approved, the Company believes its ibuprofen product would be the first and only OTC 12-hour, extended-release ibuprofen product on the market in the United States. Thu, 03 Jul 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/113831.php Aradigm Corporation (OTCBB:ARDM) (the "Company") announced positive results from an open-label, two week efficacy and safety study of its once daily inhaled liposomal ciprofloxacin in patients with cystic fibrosis (CF). The study conducted at leading CF centers in Australia and New Zealand enrolled a total of 22 patients. Thu, 03 Jul 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/113816.php NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced positive Phase I results for NP101, a novel drug-device patch for acute migraine in clinical development. Thu, 03 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113746.php Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that the Company has initiated patient enrollment in TARGET 1 and TARGET 2, its Phase 3, randomized, double-blind, placebo-controlled, multicenter studies to assess the efficacy and safety of rifaximin 550 mg, dosed three times daily, in the treatment of subjects with non-constipation irritable bowel syndrome (IBS). Thu, 03 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113736.php Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported that its lead product candidate bavituximab achieved the pre-specified Stage 1 primary endpoint in its ongoing Phase II clinical trial in patients with metastatic breast cancer. The trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of a combination of bavituximab and docetaxel in metastatic breast cancer patients. Wed, 02 Jul 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/113609.php A multicenter trial with up to five years of follow-up continues to support the mid- and long-term durability and safety of the Zenith endovascular graft used for aneurysm repair. "Our study showed that the risk of aneurysm-related death or rupture were exceptionally low, and complications of migration, limb occlusion and device integrity issues were uncommon," said Roy Greenberg, MD, director of endovascular research at The Cleveland Clinic Foundation. Wed, 02 Jul 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/113608.php The impact of surgeons' annual aortic volume and other prognostic indicators have been revealed in early outcomes of ruptured abdominal aortic aneurysm (RAAA) repair in a recent study from the University of Pittsburgh Medical Center. Details of the study have been published in the July issue of the Journal of Vascular Surgery. Fourteen different surgeons performed consecutive open RAAA repairs on 170 patients between January 2001 and June 2007 at the Center. Wed, 02 Jul 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/113571.php ORLANDO, FL (UroToday.com) - Dr. E. David Crawford presented information on challenges facing clinical trials from SWOG, ECOG and CALGB. Patient accrual for clinical trials is only 2-3%. Innumerable layers of rules and regulations have been created with numerous layers that increase costs and delays. He applauded prevention trials such as PCPT, SELECT, Toremifene for PIN and REDUCE. He gave poor marks for randomized treatment trials. Wed, 02 Jul 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/113598.php ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5-FU (5 fluorouracil), for the treatment of first-line metastatic colorectal cancer. The primary endpoint of the study was progression-free survival, which is expected to mature and be reported by the Company along with safety data later this year. Wed, 02 Jul 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/113596.php Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE) announced that it has initiated a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System (tCGM System) in patients with Type 1 and Type 2 diabetes. The Company expects to complete and announce the results of the study in the third quarter of 2008. Wed, 02 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/113499.php Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center. Tue, 01 Jul 2008 06:00:00 PDT http://www.medicalnewstoday.com/articles/113474.php Using sucrose to reduce pain in newborns undergoing painful procedures should be limited to babies having blood taken (venipuncture) for the newborn screening test but not for intramuscular injections, write Dr. Anna Taddio and co-authors. Tue, 01 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113362.php Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of data demonstrating that human immune system cells (CD4 T-cells) can be made resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases (ZFN(TM)). The data suggest that the ZFN approach, which results in the permanent modification of the CCR5 gene encoding an important receptor for HIV infection, is a promising strategy for the treatment of HIV/AIDS. Tue, 01 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113360.php Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, announced the initiation of volunteer enrollment in its Phase II clinical trial for its split pandemic influenza vaccine. The preliminary results from this study are expected to be available in early 2009. Tue, 01 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113359.php Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC). The primary objective of the study is to assess the overall response rate to the combination of bavituximab with a standard regimen of carboplatin and paclitaxel in NSCLC patients. Tue, 01 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113358.php Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, announced that it has begun enrollment for its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial evaluating CPP-109 for the treatment of patients addicted to methamphetamine. Tue, 01 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113357.php deCODE genetics (Nasdaq: DCGN) announced positive topline results from its latest clinical pharmacology study of DG041, the company's first-in-class antagonist of the EP3 receptor for prostaglandin E2, developed as a next-generation oral anti-platelet therapy for preventing arterial thrombosis without increasing bleeding risk. Tue, 01 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113355.php Emisphere Technologies, Inc. (Nasdaq: EMIS) announced that Novartis Pharma AG has launched a Phase I study in postmenopausal women to determine the safety and tolerability of oral PTH134, a combination of human PTH-1-34 and the absorption enhancer 5-CNAC using Emisphere's proprietary Eligen(R) technology, for the treatment of postmenopausal osteoporosis. Tue, 01 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113351.php An interventional cardiology team led by Professor Patrick W. Serruys successfully placed a vProtect(TM) Luminal Shield in the left anterior descending (LAD) coronary artery of a 64-year-old man at Erasmus Medical Center in Rotterdam. Tue, 01 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/113330.php Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 3 clinical trial of VIVITROL® (naltrexone for extended-release injectable suspension) for the treatment of opioid dependence. The multi-center study is designed to assess the efficacy and safety of VIVITROL in approximately 200 patients diagnosed with opioid dependence. The clinical data from this study will form the basis of a supplemental New Drug Application (sNDA) to the U.S.